Novo Nordisk Secures EMA Approval for Wegovy Delivery Flexibility
Bagsværd, Denmark | April 9, 2026 Novo Nordisk has announced that the European Medicines Agency (EMA) has approved an...
Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
Bagsværd, Denmark | April 9, 2026 Novo Nordisk has announced that the European Medicines Agency (EMA) has approved an...
MISSISSAUGA, Ontario — December 15, 2025 — Novo Nordisk Canada Inc. announced that Health Canada has granted conditional marketing...
